Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model

Molecular Neurodegeneration

Jada Lewis¹  Dennis W Dickson¹  Naruhiko Sahara¹  Joshua Knight¹  John Howard¹  Rachel M Bailey¹ 

[1] Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA

关键词: Morris water maze;    Behavior;    Neurodegeneration;    Tauopathy;    Tau;    rTg4510;    C57BL/6;    Strain background;    Transgenic mouse models;   

Others  :  861701
DOI  :  10.1186/1750-1326-9-8

 received in 2013-07-30, accepted in 2014-01-10,  发布年份 2014

【 摘 要 】

Background

Cross-breeding of transgenic mice is commonly used to assess gene-gene interactions, particularly in the context of disease. Strain background changes can influence the phenotype of mouse models and can confound crossbreeding studies. We sought to determine if changing the strain background of a commonly used mouse model of tauopathy (rTg4510) would significantly impact the originally reported phenotype. On the original F1 FVB/N x 129S6 background, rTg4510 mice present with progressive cognitive decline, increased insoluble tau, robust tau pathology and age-dependent neurodegeneration. One of the most common strains in mouse modeling is C57BL/6. We and others have previously reported that this strain background alters the phenotypes of various models, including the JNPL3 model of tauopathy. To determine if the phenotype of rTg4510 mice was similarly affected by the introduction of the C57BL/6 background, we compared rTg4510 mice on the original F1 FVB/N x 129S6 background to rTg4510 mice on an F1 FVB/N x C57BL/6NTac (B6/NTac) background, herein termed rTg4510_B6.

Results

Despite a small, but significant increase in soluble human tau levels, young rTg4510_B6 mice had equivalent levels of tau phosphorylation, aggregation and cognitive impairments as age-matched rTg4510 mice. At 6.5 months of age, rTg4510_B6 mice displayed hyperphosphorylated insoluble tau and robust cortical tau neuropathology that was equivalent to age-matched rTg4510 mice; however, 10.5-month-old rTg4510_B6 mice had greater amounts of phospho-tau in the cortex and hippocampus when compared to age-matched rTg4510 mice. Non-transgenic (NT) littermates of rTg4510_B6 (NT_B6) mice also had greater amounts of cortical and hippocampal phospho-tau at 10.5 months of age when compared to NT littermates of rTg4510 mice. Additionally, older rTg4510_B6 mice had gross forebrain neurodegeneration that was equivalent to age-matched rTg4510 mice.

Conclusions

Overall, our data shows that introduction of the C57BL/6 strain into the rTg4510 mouse background modestly alters the tau pathology that was originally reported in rTg4510 on the F1 FVB/129 background. In contrast, behavioral and neurodegenerative outcomes were not altered. These studies support the use of the rTg4510 mouse model on a partial C57BL/6 strain background without losing fidelity of the phenotype and suggest that the C57BL/6 background does not inherently protect against tauopathy.

【 授权许可】

   
2014 Bailey et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 2.

【 参考文献 】

• [1]Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, et al.: Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000, 25:402-405.
• [2]Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, et al.: Tau suppression in a neurodegenerative mouse model improves memory function. Science (New York, NY) 2005, 309:476-481.
• [3]Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC, Radde R, Staufenbiel M, Lewis J, Hutton M, Tolnay M, Jucker M: Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol 2007, 171:2012-2020.
• [4]McKinney BC, Schneider JS, Schafer GL, Lowing JL, Mohan S, Zhao MX, Heng MY, Albin RL, Seasholtz AF, Akil H, Murphy GG: Decreased locomotor activity in mice expressing tTA under control of the CaMKII alpha promoter. Genes, Brain, Behavior 2008, 7:203-213.
• [5]Han HJ, Allen CC, Buchovecky CM, Yetman MJ, Born HA, Marin MA, Rodgers SP, Song BJ, Lu HC, Justice MJ, et al.: Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator. J Neurosci 2012, 32:10574-10586.
• [6]Qiao G, Li Z, Minto AW, Shia J, Yang L, Bao L, Tschopp J, Gao JX, Wang J, Quigg RJ, Zhang J: Altered thymic selection by overexpressing cellular FLICE inhibitory protein in T cells causes lupus-like syndrome in a BALB/c but not C57BL/6 strain. Cell Death Differ 2010, 17:522-533.
• [7]Clark AG, Fan Q, Brady GF, Mackin KM, Coffman ED, Weston ML, Foster MH: Regulation of basement membrane-reactive B cells in BXSB, (NZBxNZW)F1, NZB, and MRL/lpr lupus mice. Autoimmunity 2013, 46:188-204.
• [8]Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER: Control of memory formation through regulated expression of a CaMKII transgene. Science (New York, NY) 1996, 274:1678-1683.
• [9]Krestel HE, Mayford M, Seeburg PH, Sprengel R: A GFP-equipped bidirectional expression module well suited for monitoring tetracycline-regulated gene expression in mouse. Nucleic Acids Res 2001, 29:E39.
• [10]Zhou H, Huang C, Yang M, Landel CP, Xia PY, Liu YJ, Xia XG: Developing tTA transgenic rats for inducible and reversible gene expression. Int J Biol Sci 2009, 5:171-181.
• [11]Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I: Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009, 118:53-69.
• [12]Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM: Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 1994, 39:669-673.
• [13]Weaver CL, Espinoza M, Kress Y, Davies P: Conformational change as one of the earliest alterations of tau in Alzheimer’s disease. Neurobiol Aging 2000, 21:719-727.
• [14]Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, et al.: Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 2005, 25:10637-10647.
• [15]Greenberg SG, Davies P: A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A 1990, 87:5827-5831.
• [16]O’Leary TP, Gunn RK, Brown RE: What are we measuring when we test strain differences in anxiety in mice? Behav Genet 2013, 43:34-50.
• [17]Aggleton JP, Sanderson DJ, Pearce JM: Structural learning and the hippocampus. Hippocampus 2007, 17:723-734.
• [18]Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, Hyman BT: Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 2006, 168:1598-1607.
• [19]Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, et al.: Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007, 27:3650-3662.
• [20]Ramalho RM, Viana RJ, Castro RE, Steer CJ, Low WC, Rodrigues CM: Apoptosis in transgenic mice expressing the P301L mutated form of human tau. Mol Med 2008, 14:309-317.
• [21]Spires-Jones TL, de Calignon A, Matsui T, Zehr C, Pitstick R, Wu HY, Osetek JD, Jones PB, Bacskai BJ, Feany MB, et al.: In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. J Neurosci 2008, 28:862-867.
• [22]Dickey C, Kraft C, Jinwal U, Koren J, Johnson A, Anderson L, Lebson L, Lee D, Dickson D, de Silva R, et al.: Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. Am J Pathol 2009, 174:228-238.
• [23]Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D: LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation 2010, 7:56. BioMed Central Full Text
• [24]Rocher AB, Crimins JL, Amatrudo JM, Kinson MS, Todd-Brown MA, Lewis J, Luebke JI: Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol 2010, 223:385-393.
• [25]Fox LM, William CM, Adamowicz DH, Pitstick R, Carlson GA, Spires-Jones TL, Hyman BT: Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J Neuropathol Exp Neurol 2011, 70:588-595.
• [26]Barten DM, Fanara P, Andorfer C, Hoque N, Wong PY, Husted KH, Cadelina GW, Decarr LB, Yang L, Liu V, et al.: Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J Neurosci 2012, 32:7137-7145.
• [27]Ljungberg MC, Ali YO, Zhu J, Wu CS, Oka K, Zhai RG, Lu HC: CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy. Hum Mol Genet 2012, 21:251-267.
• [28]Spires-Jones TL, Fox LM, Rozkalne A, Pitstick R, Carlson GA, Kazantsev AG: Inhibition of sirtuin 2 with sulfobenzoic acid derivative AK1 is non-toxic and potentially neuroprotective in a mouse model of frontotemporal dementia. Front Pharmacol 2012, 3:42.
• [29]Abisambra JF, Jinwal UK, Blair LJ, O’Leary JC III, Li Q, Brady S, Wang L, Guidi CE, Zhang B, Nordhues BA, et al.: Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J Neurosci 2013, 33:9498-9507.
• [30]Nash KR, Lee DC, Hunt JB Jr, Morganti JM, Selenica ML, Moran P, Reid P, Brownlow M, Guang-Yu Yang C, Savalia M, et al.: Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol Aging 2013, 34:1540-1548.
• [31]Selenica ML, Brownlow M, Jimenez JP, Lee DC, Pena G, Dickey CA, Gordon MN, Morgan D: Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy. Neurodegener Dis 2013, 11:165-181.
• [32]Clippinger AK, D’Alton S, Lin WL, Gendron TF, Howard J, Borchelt DR, Cannon A, Carlomagno Y, Chakrabarty P, Cook C, et al.: Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. Acta Neuropathol 2013, 126:39-50.
• [33]Perez PD, Hall G, Kimura T, Ren Y, Bailey RM, Lewis J, Febo M, Sahara N: In vivo functional brain mapping in a conditional mouse model of human tauopathy (tau(P301L)) reveals reduced neural activity in memory formation structures. Mol Neurodegeneration 2013, 8:9. BioMed Central Full Text
• [34]Bothe GW, Bolivar VJ, Vedder MJ, Geistfeld JG: Genetic and behavioral differences among five inbred mouse strains commonly used in the production of transgenic and knockout mice. Genes, Brain, Behavior 2004, 3:149-157.
• [35]Krezowski J, Knudson D, Ebeling C, Pitstick R, Giri RK, Schenk D, Westaway D, Younkin L, Younkin SG, Ashe KH, Carlson GA: Identification of loci determining susceptibility to the lethal effects of amyloid precursor protein transgene overexpression. Hum Mol Genet 2004, 13:1989-1997.
• [36]Bryant CD, Zhang NN, Sokoloff G, Fanselow MS, Ennes HS, Palmer AA, McRoberts JA: Behavioral differences among C57BL/6 substrains: implications for transgenic and knockout studies. J Neurogenet 2008, 22:315-331.
• [37]Mekada K, Abe K, Murakami A, Nakamura S, Nakata H, Moriwaki K, Obata Y, Yoshiki A: Genetic differences among C57BL/6 substrains. Exp Anim 2009, 58:141-149.
• [38]Zurita E, Chagoyen M, Cantero M, Alonso R, Gonzalez-Neira A, Lopez-Jimenez A, Lopez-Moreno JA, Landel CP, Benitez J, Pazos F, Montoliu L: Genetic polymorphisms among C57BL/6 mouse inbred strains. Transgenic Res 2011, 20:481-489.
• [39]Pravtcheva DD, Wise TL: Transgene instability in mice injected with an in vitro methylated Igf2 gene. Mutation Res 2003, 529:35-50.
• [40]Holmes A, Wrenn CC, Harris AP, Thayer KE, Crawley JN: Behavioral profiles of inbred strains on novel olfactory, spatial and emotional tests for reference memory in mice. Genes, Brain, Behavior 2002, 1:55-69.
• [41]Clapcote SJ, Roder JC: Survey of embryonic stem cell line source strains in the water maze reveals superior reversal learning of 129S6/SvEvTac mice. Behav Brain Res 2004, 152:35-48.
• [42]Brich J, Shie FS, Howell BW, Li R, Tus K, Wakeland EK, Jin LW, Mumby M, Churchill G, Herz J, Cooper JA: Genetic modulation of tau phosphorylation in the mouse. J Neurosci 2003, 23:187-192.
• [43]Matsuki T, Zaka M, Guerreiro R, van der Brug MP, Cooper JA, Cookson MR, Hardy JA, Howell BW: Identification of Stk25 as a genetic modifier of Tau phosphorylation in Dab1-mutant mice. PloS one 2012, 7:e31152.
• [44]Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH: Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003, 40:471-483.
• [45]Crowe A, Ksiezak-Reding H, Liu WK, Dickson DW, Yen SH: The N terminal region of human tau is present in Alzheimer’s disease protein A68 and is incorporated into paired helical filaments. Am J Pathol 1991, 139:1463-1470.
• [46]Paxinos G, Franklin KBJ: The mouse brain in stereotaxic coordinates. 2nd edition. San Diego: Academic Press; 2001.